INP104: A Drug Evaluation of a Nonoral Product for the Acute Treatment of Migraine

References

• Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia38(1), 1–211 (2018).
   PubMed Web of Science ®Google Scholar
• Agosti R . Migraine Burden of Disease: From the Patient’s Experience to a Socio-Economic View. Headache58 (Suppl. 1), 17–32 (2018).
   PubMed Web of Science ®Google Scholar
• Collaborators GBDH . Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol.17(11), 954–976 (2018).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , HollandPR , Martins-OliveiraM , HoffmannJ , SchankinC , AkermanS. Pathophysiology of migraine: a sisorder of sensory processing. Physiol. Rev.97(2), 553–622 (2017).
   PubMed Web of Science ®Google Scholar
• Edmeads J , MackellJA. The economic impact of migraine: an analysis of direct and indirect costs. Headache42(6), 501–509 (2002).
   PubMed Web of Science ®Google Scholar
• Hawkins K , WangS , RupnowM. Direct cost burden among insured US employees with migraine. Headache48(4), 553–563 (2008).
   PubMed Web of Science ®Google Scholar
• Shimizu T , SakaiF , MiyakeHet al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J. Headache Pain22(1), 29 (2021).
   PubMed Web of Science ®Google Scholar
• Burton WN , LandySH , DownsKE , RunkenMC. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin. Proc.84(5), 436–445 (2009).
   PubMed Web of Science ®Google Scholar
• Lipton RB , MunjalS , BuseDCet al. Unmet acute treatment needs From the 2017 Migraine in America Symptoms and Treatment study. Headache59(8), 1310–1323 (2019).
   PubMed Web of Science ®Google Scholar
• Latremoliere A , WoolfCJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J. Pain10(9), 895–926 (2009).
   PubMed Web of Science ®Google Scholar
• Bernstein C , BursteinR. Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. J. Clin. Neurol.8(2), 89–99 (2012).
   PubMed Web of Science ®Google Scholar
• Lipton RB , FanningKM , SerranoD , ReedML , CadyR , BuseDC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology84(7), 688–695 (2015).
   PubMed Web of Science ®Google Scholar
• Aurora SK , ShrewsburySB , RayS , HindiyehN , NguyenL. A link between gastrointestinal disorders and migraine: insights into the gut-brain connection. Headache61, 576–589 (2021).
   PubMed Web of Science ®Google Scholar
• Cámara-Lemarroy CR , Rodriguez-GutierrezR , Monreal-RoblesR , Marfil-RiveraA. Gastrointestinal disorders associated with migraine: a comprehensive review. World J. Gastroenterol.22(36), 8149–8160 (2016).
   PubMed Web of Science ®Google Scholar
• Arzani M , JahromiSR , GhorbaniZet al. Gut-brain axis and migraine headache: a comprehensive review. J. Headache Pain21(1), 15 (2020).
   PubMed Web of Science ®Google Scholar
• Shechter A , StewartWF , SilbersteinSD , LiptonRB. Migraine and autonomic nervous system function: a population-based, case-control study. Neurology58(3), 422–427 (2002).
   PubMed Web of Science ®Google Scholar
• Barbanti P , AuriliaC , Dall’armiV , EgeoG , FofiL , BonassiS. The phenotype of migraine with unilateral cranial autonomic symptoms documents increased peripheral and central trigeminal sensitization. A case series of 757 patients. Cephalalgia36(14), 1334–1340 (2016).
   PubMed Web of Science ®Google Scholar
• Schreiber CP , HutchinsonS , WebsterCJ , AmesM , RichardsonMS , PowersC. Prevalence of migraine in patients with a history of self-reported or physician-diagnosed “sinus” headache. Arch. Intern Med.164(16), 1769–1772 (2004).
   PubMedGoogle Scholar
• Hindiyeh N , AuroraSK. What the gut can teach us about migraine. Curr. Pain Headache Rep.19(7), 33 (2015).
   PubMed Web of Science ®Google Scholar
• Parkman HP . Migraine and gastroparesis from a gastroenterologist’s perspective. Headache53 (Suppl. 1), 4–10 (2013).
   PubMed Web of Science ®Google Scholar
• Rapoport AM , FreitagF , PearlmanSH. Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs24(11), 929–940 (2010).
   PubMed Web of Science ®Google Scholar
• Djupesland PG , MessinaJC , MahmoudRA. Breath powered nasal delivery: a new route to rapid headache relief. Headache53(Suppl. 2), 72–84 (2013).
   PubMed Web of Science ®Google Scholar
• The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache59(1), 1–18 (2019).
   PubMed Web of Science ®Google Scholar
• Silberstein SD . Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology55(6), 754–762 (2000).
   PubMed Web of Science ®Google Scholar
• Ashina M . Migraine. N. Engl. J. Med.383(19), 1866–1876 (2020).
   PubMed Web of Science ®Google Scholar
• Marmura MJ , SilbersteinSD , SchwedtTJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache55(1), 3–20 (2015).
   PubMed Web of Science ®Google Scholar
• Ferrari MD , GoadsbyPJ , RoonKI , LiptonRB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia22(8), 633–658 (2002).
   PubMed Web of Science ®Google Scholar
• Cortelli P , AllaisG , TulloVet al. Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. Neurol. Sci.32 (Suppl. 1), S95–98 (2011).
   PubMed Web of Science ®Google Scholar
• Géraud G , KeywoodC , SenardJM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache43(4), 376–388 (2003).
   PubMed Web of Science ®Google Scholar
• Leroux E , BuchananA , LombardLet al. Evaluation of patients with insufficient efficacy and/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. Adv. Ther.37(12), 4765–4796 (2020).
   PubMed Web of Science ®Google Scholar
• Ashcroft DM , MillsonD. Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf.13(2), 73–82 (2004).
   PubMed Web of Science ®Google Scholar
• Dodick DW , MartinV. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia24(6), 417–424 (2004).
   PubMed Web of Science ®Google Scholar
• Cady R , ElkindA , GoldsteinJ , KeywoodC. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr. Med. Res. Opin.20(9), 1465–1472 (2004).
   PubMed Web of Science ®Google Scholar
• Cady R , MartinV , MauskopAet al. Efficacy of Rizatriptan 10 mg administered early in a migraine attack. Headache46(6), 914–924 (2006).
   PubMed Web of Science ®Google Scholar
• Viana M , GenazzaniAA , TerrazzinoS , NappiG , GoadsbyPJ. Triptan nonresponders: do they exist and who are they?Cephalalgia33(11), 891–896 (2013).
   PubMed Web of Science ®Google Scholar
• Lipton RB , DodickDW , AilaniJet al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA322(19), 1887–1898 (2019).
   PubMed Web of Science ®Google Scholar
• Croop R , GoadsbyPJ , StockDAet al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet394(10200), 737–745 (2019).
   PubMed Web of Science ®Google Scholar
• Dodick DW , LiptonRB , AilaniJet al. Ubrogepant for the treatment of migraine. N. Engl. J. Med.381(23), 2230–2241 (2019).
   PubMed Web of Science ®Google Scholar
• Lipton RB , CroopR , StockEGet al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N. Engl. J. Med.381(2), 142–149 (2019).
   PubMed Web of Science ®Google Scholar
• Kuca B , SilbersteinSD , WietechaLet al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology91(24), e2222–2232 (2018).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , WietechaLA , DennehyEBet al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain142(7), 1894–1904 (2019).
   PubMed Web of Science ®Google Scholar
• REYVOW™ Package insert. Eli Lilly and Company (2021).
   Google Scholar
• Chiang CC , ArcaKN , DunnRBet al. Real-world efficacy, tolerability, and safety of ubrogepant. Headache61(4), 620–627 (2021).
   PubMed Web of Science ®Google Scholar
• Lipton RB , DodickDW , GoadsbyPJet al. Ubrogepant is effective in the acute treatment of migraine with mild pain. Migraine Trust Virtual Symposium (2020). https://journals.sagepub.com/doi/full/10.1177/0333102420962311 (Accessed May10, 2023).
   Google Scholar
• Yuan H , SpareNM , SilbersteinSD. Targeting CGRP for the prevention of migraine and cluster headache: a narrative review. Headache59 (Suppl. 2), 20–32 (2019).
   PubMed Web of Science ®Google Scholar
• Cady RK , MaizelsM , ReevesDL , LevinsonDM , EvansJK. Predictors of adherence to triptans: factors of sustained vs lapsed users. Headache49(3), 386–394 (2009).
   PubMed Web of Science ®Google Scholar
• Lombard L , FarrarM , YeWet al. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J. Headache Pain21(1), 41 (2020).
   PubMed Web of Science ®Google Scholar
• Diener HC , HolleD , SolbachK , GaulC. Medication-overuse headache: risk factors, pathophysiology and management. Nat. Rev. Neurol.12(10), 575–583 (2016).
   PubMed Web of Science ®Google Scholar
• Fregoso G , WangA , TsengK , WangJ. Transition from Acute to Chronic Pain: Evaluating Risk for Chronic Postsurgical Pain. Pain Physician22(5), 479–488 (2019).
   PubMed Web of Science ®Google Scholar
• Pozek JP , BeausangD , BarattaJL , ViscusiER. The Acute to Chronic Pain Transition: Can Chronic Pain Be Prevented?Med. Clin. North Am.100(1), 17–30 (2016).
   PubMed Web of Science ®Google Scholar
• Pak DJ , YongRJ , KayeAD , UrmanRD. Chronification of Pain: Mechanisms, Current Understanding, and Clinical Implications. Curr. Pain Headache Rep.22(2), 9 (2018).
   PubMed Web of Science ®Google Scholar
• Biagianti B , GrazziL , UsaiS , GambiniO. Dependency-like behaviors and pain coping styles in subjects with chronic migraine and medication overuse: results from a 1-year follow-up study. BMC Neurol.14, 181 (2014).
   PubMed Web of Science ®Google Scholar
• Takahashi TT , OrnelloR , QuatrosiGet al. Medication overuse and drug addiction: a narrative review from addiction perspective. J. Headache Pain22(1), 32 (2021).
   PubMed Web of Science ®Google Scholar
• Silberstein SD , ShrewsburySB , HoekmanJ. Dihydroergotamine (DHE) — then and now: a narrative review. Headache60(1), 40–57 (2020).
   PubMed Web of Science ®Google Scholar
• Baron EP , TepperSJ. Orally inhaled dihydroergotamine: reviving and improving a classic. Future Neurol.6(3), 327–333 (2011).
   Google Scholar
• Saper JR , SilbersteinS , DodickD , RapoportA. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache46(Suppl. 4), S212–S220 (2006).
   PubMed Web of Science ®Google Scholar
• Tepper SJ , KoriSH , BorlandSWet al. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia. Headache52(1), 37–47 (2012).
   PubMed Web of Science ®Google Scholar
• Morren JA , Galvez-JimenezN. Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?Expert Opin. Pharmacother.11(18), 3085–3093 (2010).
   PubMed Web of Science ®Google Scholar
• Silberstein SD , YoungWB , HopkinsMM , Gebeline-MyersC , BradleyKC. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial. Headache47(6), 878–885 (2007).
   PubMed Web of Science ®Google Scholar
• Baron EP , TepperSJ. Orally inhaled dihydroergotamine: reviving and improving a classic. Future Neurol.6(3), 327–333 (2011).
   Google Scholar
• Nagy AJ , GandhiS , BholaR , GoadsbyPJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology77(20), 1827–1832 (2011).
   PubMed Web of Science ®Google Scholar
• Kellerman DJ , ForstA , CombsDL , BorlandS , KoriS. Assessment of the consistency of absorption of dihydroergotamine following oral inhalation: pooled results from four clinical studies. J. Aerosol Med. Pulm. Drug Deliv.26(5), 297–306 (2013).
   PubMed Web of Science ®Google Scholar
• Shrewsbury SB , JelevaM , SatterlyKH , LickliterJ , HoekmanJ. STOP 101: a phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by a I123 Precision Olfactory Delivery (POD®) device, in healthy adult subjects. Headache59(3), 394–409 (2019).
   PubMed Web of Science ®Google Scholar
• Price G , PatelDA. Drug bioavailability. In: StatPearls.Treasure Island, FL (2020).
   Google Scholar
• Migranal®Package insert. Bausch Health Companies, Inc (2019).
   Google Scholar
• Hoekman JD , BrunelleA , KohringC , FullerC. inventors; Impel NeuroPharma Inc., assignee. Medical unit dose container. US patent 10,537,692. January 21, 2020.
   Google Scholar
• Aurora SK , SilbersteinSD , KoriSHet al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache51(4), 507–517 (2011).
   PubMed Web of Science ®Google Scholar
• Gänger S , SchindowskiK. Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics10(3), 116 (2018).
   PubMed Web of Science ®Google Scholar
• Hoekman J , RayS , AuroraSK , ShrewsburySB. The upper nasal space—a novel delivery route ideal for central nervous system drugs. US Neurol.16(1), 25–31 (2020).
   Google Scholar
• Chamanza R , WrightJA. A Review of the Comparative Anatomy, Histology, Physiology and Pathology of the Nasal Cavity of Rats, Mice, Dogs and Non-human Primates. Relevance to Inhalation Toxicology and Human Health Risk Assessment. J. Comp. Pathol.153(4), 287–314 (2015).
   PubMed Web of Science ®Google Scholar
• Djupesland PG , MessinaJC , MahmoudRA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther. Deliv.5(6), 709–733 (2014).
   PubMedGoogle Scholar
• Martin V , HoekmanJ , AuroraSK , ShrewsburySB. Nasal Delivery of Acute Medications for Migraine: The Upper Versus Lower Nasal Space. J. Clin. Med.10(11), (2021).
   Web of Science ®Google Scholar
• Djupesland PG . Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv. Transl. Res.3(1), 42–62 (2013).
   PubMed Web of Science ®Google Scholar
• Lochhead JJ , ThorneRG. Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev.64(7), 614–628 (2012).
   PubMed Web of Science ®Google Scholar
• Chari S , SridharK , WalengaR , KleinstreuerC. Computational analysis of a 3D mucociliary clearance model predicting nasal drug uptake. J. Aerosol Sci.155, 105757 (2021).
   Web of Science ®Google Scholar
• Hoekman JD , HoRJ. Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution. AAPS PharmSciTech12(2), 534–543 (2011).
   PubMed Web of Science ®Google Scholar
• Smith TR , WinnerP , AuroraSK , JelevaM , Hocevar-TrnkaJ , ShrewsburySB. STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD(®)) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache61(8), 1214–1226 (2021).
   PubMed Web of Science ®Google Scholar
• TRUDHESA™ Package insert. Impel NeuroPharma, Inc (2021).
   Google Scholar
• Cooper W , RayS , AuroraSKet al. Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action. J. Aerosol Med. Pulm. Drug Deliv.35(6), 321–332 (2022).
   PubMed Web of Science ®Google Scholar
• Silberstein SD , KoriSH. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs27(5), 385–394 (2013).
   PubMed Web of Science ®Google Scholar
• Lipton RB . Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache37 (Suppl. 1), S33–41 (1997).
   PubMed Web of Science ®Google Scholar
• Silberstein SD . The pharmacology of ergotamine and dihydroergotamine. Headache37 (Suppl. 1), S15–25 (1997).
   PubMed Web of Science ®Google Scholar
• De Vries T , VillalonCM , MaassenvandenbrinkA. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol. Ther.211, 107528 (2020).
   PubMed Web of Science ®Google Scholar
• Silberstein SD , MccroryDC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache43(2), 144–166 (2003).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P , SaxenaPR , DahlöfCet al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain123 (Pt 1), 9–18 (2000).
   PubMedGoogle Scholar
• Cook RO , ShrewsburySB , RamadanNM. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism. Headache49(10), 1423–1434 (2009).
   PubMed Web of Science ®Google Scholar
• Kori S , ZhangJ , KellermanD , ArmerT , PGG. Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT 1D receptors. J Headache Pain14(Suppl. 1), 75 (2013).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ . Migraine, Allodynia, Sensitisation and All of That. Eur Neurol53(Suppl. 1), 10–16 (2005).
   PubMedGoogle Scholar
• Craig K , HoekmanJ , JelevaM , Hocevar-TrnkaJ , AuroraSK , ShrewsburyS. Cardiovascular Safety Results of INP104 (POD-DHE) from the STOP 301 Phase 3 Study (2493). Neurology96(Suppl. 15), 2493 (2021).
   Web of Science ®Google Scholar
• Davis G , PranskySM , FatakiaA , ShrewsburyS. The Upper Nasal Space as a Promising New Route for Drug Administration: Implications for Nasal Safety Assessments From the Pivotal STOP 301 Study of INP104. Ann. Otolaryngol. Rhinol.9(5), 1303 (2022).
   Google Scholar
• Saper JR , SilbersteinS. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache46 (Suppl. 4), S171–181 (2006).
   PubMed Web of Science ®Google Scholar
• Kellerman D , KoriS , ForstAet al. Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans. Cephalalgia32(2), 150–158 (2012).
   PubMed Web of Science ®Google Scholar